Yago Nieto, MD, PhD, discusses AFM13, how it works, and its effect as a bispecific antibody that targets CD30 and CD16.

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

Uday R. Popat, MD, discusses promising findings from a phase 2 trial evaluating the JAK inhibitor itacitinib combined with ...

Follicular lymphoma is an indolent malignancy with a generally favorable prognosis, with survival often measured in decades.

A 2012 study of patients with low-tumor-burden follicular lymphoma showed that the 4-year freedom from treatment failure rate ...

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biopharmaceutical company leveraging its proprietary RADR® artificial ...

BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical company developing innovative cancer therapies, today announced its financial results for ...